A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*

Background It is unclear what constitutes a clinically-meaningful response for allergic rhinitis (AR) outcomes. In a recent survey [1] most experts defined control as being “hardly troubled at all” by each symptom. We propose a new criterion of ≤1 point remaining in each nasal symptom score (Max AM+PM score for each symptom=6) of the reflective total nasal symptom score (rTNSS) to stringently test efficacy and provide an endpoint meaningful to physicians and patients. This criterion has been termed complete/near-to-complete symptom control. Any treatment providing this level of control (patients will feel “cured”) should have considerable socioeconomic impact.